# Electroporation Potentiated Immunotherapy in Cancer

> **NCT04835402** · PHASE2 · UNKNOWN · sponsor: **Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery** · enrollment: 8 (actual)

## Conditions studied

- Pancreas Cancer, Metastatic

## Interventions

- **DRUG:** Pembrolizumab
- **DEVICE:** Irreversible electroporation

## Key facts

- **NCT ID:** NCT04835402
- **Lead sponsor:** Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-26
- **Primary completion:** 2022-03-07
- **Final completion:** 2025-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835402, "Electroporation Potentiated Immunotherapy in Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04835402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*